Novo Nordisk's CagriSema Falls Short; Eli Lilly Gains

Novo Nordisk's Phase 3 trial results for its obesity drug CagriSema revealed a 20.4% average weight loss, falling short of the anticipated 25% and trailing competitor Eli Lilly's tirzepatide. Analysts from UBS and Jefferies noted the trial's underwhelming results, predicting a decline in Novo's stock value and highlighting potential gastrointestinal tolerability issues with CagriSema. Concurrently, Eli Lilly's weight-loss drug Zepbound received FDA approval for treating obstructive sleep apnea in adults with obesity, marking it as the first drug for this condition and potentially expanding its insurance coverage. Zepbound's approval is based on studies showing significant improvements in sleep apnea symptoms and weight reduction. These developments position Eli Lilly favorably against Novo Nordisk in the competitive landscape of weight-loss treatments. Novo Nordisk's stock has responded negatively to their trial results, with technical indicators suggesting a continued bearish trend.